Literature DB >> 7680860

The measurement of polyglutamate metabolites of the thymidylate synthase inhibitor, ICI D1694, in mouse and human cultured cells.

W Gibson1, G M Bisset, P R Marsham, L R Kelland, I R Judson, A L Jackman.   

Abstract

A method is described for the measurement of the polyglutamates of the quinazoline thymidylate synthase inhibitor, N-(5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin- 6-ylmethyl)-N-methylamino]-2-theonyl)-L-glutamic acid (ICI D1694). This involved incubation of cells with [5-3H]ICI D1694, extraction of the polyglutamates and their analysis by HPLC using an ion-pairing method. Co-chromatography with ICI D1694 and its synthetic di-hexaglutamate standards (UV detection) aided identification of the [3H]polyglutamates in the fractions recovered from the HPLC. Recovery of the polyglutamates at each stage of extraction and analysis was very good (77-84% overall recovery). Polyglutamates readily accumulated as the tri-, tetra and penta forms and occasionally a small amount of hexaglutamate was found. After mouse L1210 leukemia or human W1L2 lymphoblastoid cells were incubated for 30 min with 0.1 microM [3H]ICI D1694 there was a approximately 6-fold concentration effect intracellularly with most of the 3H associated with polyglutamate forms (approximately 75% and 96% for the L1210 and W1L2, respectively). Even some of the higher chain length tetra- and pentaglutamates could be detected at this time. After 4 hr incubation the total level of intracellular 3H had risen to 2-3 microM, greater than 96% of which was associated with polyglutamates (mainly tetra- and pentaglutamates). Four other human cell lines, two ovarian (CH1 and 41M), the MCF-7 breast and the HT-29 colon, were examined for their ability to form intracellular polyglutamates. A 4 hr incubation with 0.1 microM [3H]ICI D1694 resulted in a substantial intracellular accumulation of the drug (20-100-fold) in its polyglutamate forms with only 2-20% remaining as the parent monoglutamate, depending on the cell line. The major polyglutamate was again cell line dependent, ranging from the tri to the penta form. Prolonging the incubation time to 24 hr allowed a further accumulation of drug with a larger percentage appearing as tri- to hexaglutamates. Although cell lines differed in the total level of polyglutamates formed and the pattern of chain length observed, rapid and extensive polyglutamation of ICI D1694 occurred in all the cell types examined.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7680860     DOI: 10.1016/0006-2952(93)90170-2

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  11 in total

1.  Potent dual thymidylate synthase and dihydrofolate reductase inhibitors: classical and nonclassical 2-amino-4-oxo-5-arylthio-substituted-6-methylthieno[2,3-d]pyrimidine antifolates.

Authors:  Aleem Gangjee; Yibin Qiu; Wei Li; Roy L Kisliuk
Journal:  J Med Chem       Date:  2008-09-25       Impact factor: 7.446

2.  Design, synthesis, biological evaluation and X-ray crystal structure of novel classical 6,5,6-tricyclic benzo[4,5]thieno[2,3-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors.

Authors:  Xin Zhang; Xilin Zhou; Roy L Kisliuk; Jennifer Piraino; Vivian Cody; Aleem Gangjee
Journal:  Bioorg Med Chem       Date:  2011-04-09       Impact factor: 3.641

Review 3.  Raltitrexed. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer.

Authors:  N S Gunasekara; D Faulds
Journal:  Drugs       Date:  1998-03       Impact factor: 9.546

Review 4.  Tomudex (ZD1694): from concept to care, a programme in rational drug discovery.

Authors:  A L Jackman; F T Boyle; K R Harrap
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

5.  Design, synthesis, and X-ray crystal structure of classical and nonclassical 2-amino-4-oxo-5-substituted-6-ethylthieno[2,3-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors and as potential antitumor agents.

Authors:  Aleem Gangjee; Wei Li; Roy L Kisliuk; Vivian Cody; Jim Pace; Jennifer Piraino; Jennifer Makin
Journal:  J Med Chem       Date:  2009-08-13       Impact factor: 7.446

6.  Design, synthesis, and biological evaluation of classical and nonclassical 2-amino-4-oxo-5-substituted-6-methylpyrrolo[3,2-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors.

Authors:  Aleem Gangjee; Wei Li; Jie Yang; Roy L Kisliuk
Journal:  J Med Chem       Date:  2007-12-12       Impact factor: 7.446

7.  Cellular pharmacokinetics of ZD1694 in cultured human leukaemia cells sensitive, or made resistant, to this drug.

Authors:  Y Takemura; W Gibson; R Kimbell; H Kobayashi; H Miyachi; A L Jackman
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

8.  Comparison of plasma and tissue levels of ZD1694 (Tomudex), a highly polyglutamatable quinazoline thymidylate synthase inhibitor, in preclinical models.

Authors:  G W Aherne; E Ward; N Lawrence; D Dobinson; S J Clarke; H Musgrove; F Sutcliffe; T Stephens; A L Jackman
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

9.  The renal effects of the water-soluble, non-folylpolyglutamate synthetase-dependent thymidylate synthase inhibitor ZD9331 in mice.

Authors:  M I Walton; F Mitchell; G W Aherne; C J Medlow; F T Boyle; A L Jackman
Journal:  Br J Cancer       Date:  1998-12       Impact factor: 7.640

10.  Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines.

Authors:  A L Jackman; L R Kelland; R Kimbell; M Brown; W Gibson; G W Aherne; A Hardcastle; F T Boyle
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.